Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016
Published Aug 10, 2016
116 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA)
- The report reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Spinal Muscular Atrophy (SMA) therapeutics and enlists all their major and minor projects
- The report assesses Spinal Muscular Atrophy (SMA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devis

  
Source:
Document ID
GMDHC8336IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Spinal Muscular Atrophy (SMA) Overview101
Therapeutics Development112
  Pipeline Products for Spinal Muscular Atrophy (SMA) Overview111
  Pipeline Products for Spinal Muscular Atrophy (SMA) Comparative Analysis121
Spinal Muscular Atrophy (SMA) Therapeutics under Development by Companies132
Spinal Muscular Atrophy (SMA) Therapeutics under Investigation by Universities/Institutes151
Spinal Muscular Atrophy (SMA) Pipeline Products Glance163
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
Spinal Muscular Atrophy (SMA) Products under Development by Companies191
Spinal Muscular Atrophy (SMA) Products under Investigation by Universities/Institutes201
Spinal Muscular Atrophy (SMA) Companies Involved in Therapeutics Development2116
  Astellas Pharma Inc.211
  AveXis, Inc.221
  Bio Blast Pharma Ltd.231
  Cytokinetics, Inc.241
  F. Hoffmann-La Roche Ltd.251
  Genethon261
  Genzyme Corporation271
  Ionis Pharmaceuticals, Inc.281
  Neurodyn Inc.291
  Neurotune AG301
  Novartis AG311
  Paratek Pharmaceuticals, Inc.321
  RaNA Therapeutics, Inc.331
  Sarepta Therapeutics, Inc.341
  Voyager Therapeutics, Inc.351
  WAVE Life Sciences Ltd.361
Spinal Muscular Atrophy (SMA) Therapeutics Assessment379
  Assessment by Monotherapy Products371
  Assessment by Target382
  Assessment by Mechanism of Action402
  Assessment by Route of Administration422
  Assessment by Molecule Type442
Drug Profiles4655
  AAD-2004 Drug Profile461
  ALB-111 Drug Profile471
  Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy Drug Profile481
  Antisense Oligonucleotides for Spinal Muscular Atrophy Drug Profile491
  AVXS-101 Drug Profile503
  azithromycin Drug Profile531
  CK-2127107 Drug Profile544
  Gene Therapy to Activate SMN for Spinal Muscular Atrophy Drug Profile581
  Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile591
  Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile601
  LMI-070 Drug Profile611
  ND-602 Drug Profile621
  NT-1654 Drug Profile631
  nusinersen Drug Profile646
  olesoxime Drug Profile705
  Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy Drug Profile751
  Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Drug Profile761
  PMO-25 Drug Profile771
  PTKSMA-1 Drug Profile781
  RG-7800 Drug Profile792
  RG-7916 Drug Profile811
  Small Molecules for Central Nervous System Disorders Drug Profile821
  Small Molecules for Spinal Muscular Atrophy Drug Profile831
  Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile841
  Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile851
  Small Molecules to Activate Survival Motor Neuron Protein for Spinal Muscular Atrophy Drug Profile861
  Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders Drug Profile871
  Small Molecules to Inhibit GSK-3 for Spinal Muscular Atrophy Drug Profile881
  tirasemtiv Drug Profile8911
  VYSMN-101 Drug Profile1001
Spinal Muscular Atrophy (SMA) Dormant Projects1012
Spinal Muscular Atrophy (SMA) Discontinued Products1031
Spinal Muscular Atrophy (SMA) Product Development Milestones10411
  Featured News &Press Releases1041
    Apr 21, 2016: Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise1041
    Mar 31, 2016: Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA1051
    Mar 23, 2016: RaNA Therapeutics Presents Data on Advances in RNA Therapy Targeting Spinal Muscular Atrophy1051
    Jan 12, 2016: Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy1061
    Jan 07, 2016: Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development1061
    Jan 04, 2016: Cytokinetics Announces Start Of Phase 2 Clinical Trial Of Ck-2127107 In Patients With Spinal Muscular Atrophy1071
    Oct 15, 2015: Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies1081
    Oct 04, 2015: Phase 2 Data from Spinal Muscular Atrophy Program Presented at the 20th International Annual Congress of the World Muscle Society1091
    Jul 14, 2015: Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN in Children With Spinal Muscular Atrophy1101
    Jun 22, 2015: BioBlast Announces Positive Preclinical Proof-Of-Concept Results Of Its Novel Read- through Platform in Spinal Muscular Atrophy1101
    Jun 22, 2015: Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy1111
    Jun 19, 2015: Cytokinetics Presents Results From Phase I Studies Of Ck-21271071121
    Jun 18, 2015: BioBlast Pharma to Present Preclinical Proofs of Concept in Spinal Muscular Atrophy at Two Leading Scientific Meetings in June1121
    Jun 11, 2015: Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy1131
    Apr 20, 2015: Phase 1 Data from Spinal Muscular Atrophy Program to be Presented at the 2015 American Academy of Neurology Annual Meeting1141
Appendix1152
  Methodology1151
  Coverage1151
  Secondary Research1151
  Primary Research1151
  Expert Panel Validation1151
  Contact Us1151
  Disclaimer1161

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Spinal-Muscular-Atrophy-SMA-Pipeline-Review-H2-2016-2088-16344>
  
APA:
Global Markets Direct - Market Research. (2016). Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Spinal-Muscular-Atrophy-SMA-Pipeline-Review-H2-2016-2088-16344>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.